AI Policy and the New Administration: Implications for FDA-Regulated Industries

Government and regulatory partner Barrett Tenbarge joined a panel at the Food & Drug Law Institute’s 2025 Annual Conference titled “AI Policy and the New Administration: Implications for FDA-Regulated Industries.”

The panelists discussed the policy directives coming from the Trump Administration, including the Food and Drug Administration’s draft guidance on AI regulation decision making for drugs and biologics, with a focus on how different AI-related objectives will affect FDA-regulated industries.

Visit the event's website for more information